78 related articles for article (PubMed ID: 31038849)
1. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
[TBL] [Abstract][Full Text] [Related]
2. [Optimal search conditions for identification of patients with chronic myeloid leukemia from Japanese National Health Insurance data].
Shoji-Asahina A; Nakatani E; Sato Y; Ono T; Tabara Y
Rinsho Ketsueki; 2024; 65(2):99-101. PubMed ID: 38448006
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population-based cohort study.
Fleischer T; Chang TT; Chiang JH; Chang CM; Hsieh CY; Yen HR
Cancer Med; 2016 Apr; 5(4):640-8. PubMed ID: 26773538
[TBL] [Abstract][Full Text] [Related]
4. Use of medical administrative data for the surveillance of psychotic disorders in France.
Chan Chee C; Chin F; Ha C; Beltzer N; Bonaldi C
BMC Psychiatry; 2017 Dec; 17(1):386. PubMed ID: 29202735
[TBL] [Abstract][Full Text] [Related]
5. Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.
Radivoyevitch T; Hlatky L; Landaw J; Sachs RK
Blood; 2012 May; 119(19):4363-71. PubMed ID: 22353999
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of multiple sclerosis in France in 2021: Data from the French health insurance database.
Pierret C; Mainguy M; Leray E
Rev Neurol (Paris); 2024 May; 180(5):429-437. PubMed ID: 38423846
[TBL] [Abstract][Full Text] [Related]
7. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
El-Ashwah S; Salmanton-García J; Bilgin YM; Itri F; Žák P; Weinbergerová B; Verga L; Omrani AS; Silva MGD; Szotkowski T; Marchetti M; Buquicchio C; Nucci M; Schönlein M; Farina F; Besson C; Prezioso L; Nizamuddin S; Dávila-Valls J; Martín-Pérez S; Bonuomo V; Van Doesum J; Tisi MC; Passamonti F; Méndez GA; Meers S; Maertens J; López-García A; Glenthøj A; Bonnani M; Rinaldi I; Ormazabal-Vélez I; Labrador J; Kulasekararaj A; Espigado I; Demirkan F; De Jonge N; Collins GP; Calbacho M; Blennow O; Al-Khabori M; Adžić-Vukičević T; Arellano E; Mišković B; Mladenović M; Nordlander A; Ráčil Z; Ammatuna E; Cordoba R; Hersby DS; Gräfe S; Emarah Z; Hanakova M; Sacchi MV; Ijaz M; Rahimli L; Nunes Rodrigues R; Zambrotta GPM; Marchesi F; Cornely OA; Pagano L
Leuk Lymphoma; 2024 Feb; 65(2):199-208. PubMed ID: 37966980
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the French National Health Insurance Information System as a tool for epidemiological surveillance of malaria.
Delon F; Mayet A; Thellier M; Kendjo E; Michel R; Ollivier L; Chatellier G; Desjeux G
J Am Med Inform Assoc; 2017 May; 24(3):588-595. PubMed ID: 28040684
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, demographic and spatial distribution of treated epilepsy in France in 2020: a study based on the French national health data system.
Coste J; Mandereau-Bruno L; Carcaillon-Bentata L; Mikaeloff Y; Bouilleret V
J Neurol; 2024 Jan; 271(1):519-525. PubMed ID: 37787813
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data.
Keovilayhong S; Mulliez A; Feral L; Chenaf C; Clavelou P; Moisset X; Taithe F; Poncet Megemont L
Rev Neurol (Paris); 2024 May; 180(5):451-458. PubMed ID: 38582663
[TBL] [Abstract][Full Text] [Related]
11. Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017.
Daskalakis M; Feller A; Noetzli J; Bonadies N; Arndt V; Baerlocher GM; The Nicer Working Group
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944892
[TBL] [Abstract][Full Text] [Related]
12. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
Sasaki K; Morita K; Kantarjian H; Garcia-Manero G; Jabbour E; Ravandi F; Konopleva M; Borthakur G; Wierda W; Daver N; Takahashi K; DiNardo C; Bravo GM; Issa GC; Pierce SA; Soltysiak KA; Tingen MS; Cortes JE
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e369-e378. PubMed ID: 37690903
[TBL] [Abstract][Full Text] [Related]
13. Increase in the Life Expectancy of Patients with Cancer in the United States.
Devasia TP; Howlader N; Dewar RA; Stevens JL; Mittu K; Mariotto AB
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):196-205. PubMed ID: 38015774
[TBL] [Abstract][Full Text] [Related]
14. Performance of administrative databases for identifying individuals with multiple sclerosis.
Ducatel P; Debouverie M; Soudant M; Guillemin F; Mathey G; Epstein J
Sci Rep; 2023 Oct; 13(1):18310. PubMed ID: 37880330
[TBL] [Abstract][Full Text] [Related]
15. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
Suttorp M; Metzler M; Millot F
World J Clin Oncol; 2020 Jun; 11(6):308-319. PubMed ID: 32874947
[TBL] [Abstract][Full Text] [Related]
16. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
17. Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study.
Conte C; Vayr F; Pajiep MC; Despas F; Huguet F; Mestre ML; Gauthier M; Herin F
Support Care Cancer; 2022 Jun; 30(6):5431-5440. PubMed ID: 35304631
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France.
Pajiep M; Conte C; Huguet F; Gauthier M; Despas F; Lapeyre-Mestre M
Front Oncol; 2021; 11():675609. PubMed ID: 34660261
[TBL] [Abstract][Full Text] [Related]
19. Health state utility and quality of life measures in patients with chronic myeloid leukemia in France.
S F; P CM; A GB; M D; R K; P TB; J B
Qual Life Res; 2021 Jul; 30(7):2021-2032. PubMed ID: 33651280
[TBL] [Abstract][Full Text] [Related]
20. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
Malagola M; Iurlo A; Abruzzese E; Bonifacio M; Stagno F; Binotto G; D'Adda M; Lunghi M; Crugnola M; Ferrari ML; Lunghi F; Castagnetti F; Rosti G; Lemoli RM; Sancetta R; Coppi MR; Corsetti MT; Rege Cambrin G; Romano A; Tiribelli M; Russo Rossi A; Russo S; Aprile L; Bocchia M; Gandolfi L; Farina M; Bernardi S; Polverelli N; Roccaro AM; De Vivo A; Baccarani M; Russo D
Cancer Med; 2021 Mar; 10(5):1726-1737. PubMed ID: 33594821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
